Analyst Price Target is $60.14
▲ +96.16% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Stoke Therapeutics in the last 3 months. The average price target is $60.14, with a high forecast of $76.00 and a low forecast of $35.00. The average price target represents a 96.16% upside from the last price of $30.66.
Current Consensus is
The current consensus among 9 contributing investment analysts is to buy stock in Stoke Therapeutics. This Buy consensus rating has held steady for over two years.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.